Lung Cancer – Non-Small Cell


Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (06-5-2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer (04-24-2018)

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (04-11-2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations (01-24-2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant... Continue Reading

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (01-17-2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (01-8-2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (12-6-2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer (11-13-2017)

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December... Continue Reading

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (09-21-2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC)... Continue Reading

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer (03-11-2015)

The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based... Continue Reading

Next Page »